blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1930011

EP1930011 - Crystalline form of ibandronate sodium [Right-click to bookmark this link]
StatusOpposition rejected
Status updated on  15.04.2016
Database last updated on 11.05.2024
Most recent event   Tooltip15.04.2016Opposition rejectedpublished on 18.05.2016  [2016/20]
Applicant(s)For all designated states
Teva Pharmaceutical Industries Ltd
5 Basel Street
PO Box 3190
49131 Petah Tiqva / IL
[N/P]
Former [2008/24]For all designated states
Teva Pharmaceutical Industries Ltd
5 Basel Street PO Box 3190
49131 Petah Tiqva / IL
Inventor(s)01 / Lifshitz-Liron, Revital
Hapalmach 17/1
Hertzlia 46739 / IL
02 / Bayer, Thomas
Ben Ezra 11/2
64246 Tel Aviv / IL
03 / Aronhime, Judith
Rehov Harav Maor losef 5a
76217 Rehovot / IL
 [2008/24]
Representative(s)D Young & Co LLP
3 Noble Street
London EC2V 7BQ / GB
[N/P]
Former [2013/12]Gallagher, Kirk James, et al
D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Former [2008/24]Russell, Tim, et al
D Young & Co 120 Holborn
London EC1N 2DY / GB
Application number, filing date08002626.323.08.2005
[2008/24]
Priority number, dateUS20040604026P23.08.2004         Original published format: US 604026 P
US20050690867P16.06.2005         Original published format: US 690867 P
[2008/24]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP1930011
Date:11.06.2008
Language:EN
[2008/24]
Type: A3 Search report 
No.:EP1930011
Date:18.06.2008
[2008/25]
Type: B1 Patent specification 
No.:EP1930011
Date:17.08.2011
Language:EN
[2011/33]
Search report(s)(Supplementary) European search report - dispatched on:EP20.05.2008
ClassificationIPC:A61K31/663, A61P19/10, C07F9/38
[2008/24]
CPC:
C07F9/3873 (EP,US); A61K31/663 (KR); A61P19/08 (EP);
A61P19/10 (EP); A61P3/00 (EP); A61P35/00 (EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2008/24]
TitleGerman:Kristalline Form des Ibandronat-Natriums[2008/24]
English:Crystalline form of ibandronate sodium[2008/24]
French:Forme cristalline de ibandronate de sodium[2008/24]
Examination procedure28.02.2008Examination requested  [2008/24]
10.07.2008Despatch of a communication from the examining division (Time limit: M04)
14.11.2008Reply to a communication from the examining division
03.05.2010Despatch of a communication from the examining division (Time limit: M04)
27.05.2010Reply to a communication from the examining division
30.06.2010Observations by third parties
07.07.2010Communication of intention to grant the patent
05.11.2010Fee for grant paid
05.11.2010Fee for publishing/printing paid
Parent application(s)   TooltipEP05791142.2  / EP1713489
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20050791142) is  05.09.2007
Opposition(s)Opponent(s)01  14.05.2012  23.05.2012  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
von Seebach, Malte
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
 02  16.05.2012    ADMISSIBLE
Helm AG
Nordkanalstrasse 28
20097 Hamburg / DE
Opponent's representative
von Seebach, Malte
Maiwald Patentanwalts GmbH
Jungfernstieg 38
20354 Hamburg / DE
 [N/P]
Former [2012/26]
Opponent(s)01  14.05.2012  23.05.2012  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
von Seebach, Malte
Maiwald Patentanwalts GmbH Jungfernstieg 38
20354 Hamburg / DE
 02  16.05.2012    ADMISSIBLE
Helm AG
Nordkanalstrasse 28
20097 Hamburg / DE
Opponent's representative
von Seebach, Malte
Maiwald Patentanwalts GmbH Jungfernstieg 38
20354 Hamburg / DE
03.07.2012Invitation to proprietor to file observations on the notice of opposition
01.11.2012Reply of patent proprietor to notice(s) of opposition
22.11.2013Date of oral proceedings
19.12.2013Despatch of minutes of oral proceedings
09.01.2014Despatch of communication that the patent will be revoked
19.06.2015Legal effect of rejection of opposition [2016/20]
19.11.2015Date of despatch of rejection of opposition
Appeal following opposition06.03.2014Appeal received No.  T0517/14
09.05.2014Statement of grounds filed
19.06.2015Result of appeal procedure: maintenance in unamended form
19.06.2015Date of oral proceedings
26.06.2015Minutes of the oral proceedings despatched
Fees paidRenewal fee
28.02.2008Renewal fee patent year 03
28.02.2008Renewal fee patent year 04
24.08.2009Renewal fee patent year 05
25.08.2010Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT17.08.2011
BE17.08.2011
CY17.08.2011
CZ17.08.2011
DK17.08.2011
EE17.08.2011
FI17.08.2011
LT17.08.2011
LV17.08.2011
NL17.08.2011
PL17.08.2011
RO17.08.2011
SE17.08.2011
SI17.08.2011
SK17.08.2011
TR17.08.2011
IE23.08.2011
LU23.08.2011
MC31.08.2011
BG17.11.2011
GR18.11.2011
IS17.12.2011
[2013/44]
Former [2013/29]AT17.08.2011
BE17.08.2011
CY17.08.2011
CZ17.08.2011
DK17.08.2011
EE17.08.2011
FI17.08.2011
LT17.08.2011
LV17.08.2011
NL17.08.2011
PL17.08.2011
RO17.08.2011
SE17.08.2011
SI17.08.2011
SK17.08.2011
IE23.08.2011
LU23.08.2011
MC31.08.2011
BG17.11.2011
GR18.11.2011
IS17.12.2011
Former [2012/23]AT17.08.2011
BE17.08.2011
CY17.08.2011
CZ17.08.2011
EE17.08.2011
FI17.08.2011
LT17.08.2011
LV17.08.2011
NL17.08.2011
PL17.08.2011
RO17.08.2011
SE17.08.2011
SI17.08.2011
SK17.08.2011
MC31.08.2011
GR18.11.2011
IS17.12.2011
Former [2012/21]AT17.08.2011
BE17.08.2011
CY17.08.2011
CZ17.08.2011
FI17.08.2011
LT17.08.2011
LV17.08.2011
NL17.08.2011
PL17.08.2011
SE17.08.2011
SI17.08.2011
MC31.08.2011
GR18.11.2011
IS17.12.2011
Former [2012/18]AT17.08.2011
BE17.08.2011
CY17.08.2011
FI17.08.2011
LT17.08.2011
LV17.08.2011
NL17.08.2011
PL17.08.2011
SE17.08.2011
SI17.08.2011
MC31.08.2011
GR18.11.2011
IS17.12.2011
Former [2012/17]AT17.08.2011
BE17.08.2011
CY17.08.2011
FI17.08.2011
LT17.08.2011
LV17.08.2011
NL17.08.2011
PL17.08.2011
SE17.08.2011
SI17.08.2011
GR18.11.2011
IS17.12.2011
Former [2012/12]AT17.08.2011
CY17.08.2011
FI17.08.2011
LT17.08.2011
LV17.08.2011
NL17.08.2011
PL17.08.2011
SE17.08.2011
SI17.08.2011
GR18.11.2011
IS17.12.2011
Documents cited:Search[E]WO2006002348  (TEVA PHARMACEUTICAL INDUSTIES [IL], et al) [E] 1-59 * claims 49-52 *;
 [Y]  - MONIER-FAUGERE M-C ET AL, "A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs", JOURNAL OF BONE AND MINERAL RESEARCH, (1993), vol. 8, no. 11, ISSN 0884-0431, pages 1345 - 1355, XP009064673 [Y] 1-4 * the whole document *
 [Y]  - CAIRA M R, "Crystalline polymorphism of organic compounds", TOPICS IN CURRENT CHEMISTRY, (1998), vol. 198, ISSN 0340-1022, pages 163 - 208, XP001156954 [Y] 1-4 * the whole document *

DOI:   http://dx.doi.org/10.1007/3-540-69178-2_5
ExaminationWO9623505
 DE19637890
 DE19828450
 EP0998932
 EP0998933
 WO0071104
 WO0152859
 WO0185217
 WO0197788
 WO0243738
 EP1228761
 WO03095029
    - MUEHLBAUER R.C. ET AL, "BM 21.0955, a potent new bisphosphonate to inhibit bone resorption", JOURNAL OF BONE AND MINERAL RESEARCH, (199109), vol. 6, no. 9, ISSN 0884-0431, pages 1003 - 1011, XP009064674
    - RIZZOLI R. ET AL, "Inhibition of bone resorption by the bisphosphonate BM 21.0955 is not associated with an alteration of the renal handling of calcium in rats infused with parathyroid hormone-related protein", BONE, (199207), vol. 13, no. 4, doi:10.1016/8756-3282(92)90077-A, ISSN 8756-3282, pages 321 - 325, XP026175495

DOI:   http://dx.doi.org/10.1016/8756-3282(92)90077-A
    - SAHNI M. ET AL, "Bisphosphonates act on rat bone resorption through the mediation of osteoblasts", JOURNAL OF CLINICAL INVESTIGATION, (199305), vol. 91, no. 5, doi:10.1172/JCI116422, ISSN 0021-9738, pages 2004 - 2011, XP000892358

DOI:   http://dx.doi.org/10.1172/JCI116422
    - PECHERSTORFER M. ET AL, "Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy", JOURNAL OF CLINICAL ONCOLOGY, (199601), vol. 14, no. 1, ISSN 0732-183X, pages 268 - 276, XP009064704
    - FOGED N.T. ET AL, "Quantification of the collagenolytic activity of isolated osteoclasts by enzyme-linked immunosorbent assay", JOURNAL OF BONE AND MINERAL RESEARCH, (1996), vol. 11, no. 2, ISSN 0884-0431, pages 226 - 237, XP009064672
    - PECHERSTORFER M. ET AL, "Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection", JOURNAL OF BONE AND MINERAL RESEARCH, (199605), vol. 11, no. 5, ISSN 0884-0431, pages 587 - 593, XP009064675
    - AMIN D. ET AL, "1-Hydroxy-3-(methylpentylamino)-propylidene-1,1,-bisphosphonic acid as a potent inhibitor of squalene synthase", ARZNEIMITTEL FORSCHUNG - DRUG RESEARCH, (199608), vol. 46, no. 8, ISSN 0004-4172, pages 759 - 762, XP000676630
    - RADER C.P. ET AL, "TNFalpha-Sekretion durch Abriebpartikel im humanen Markophagenmodell under deren Modulation durch Medikamente - TNF response of macrophages to wear particles, and its modification by drugs", BIOMEDIZINISCHE TECHNIK, (199905), vol. 44, no. 5, ISSN 0013-5585, pages 135 - 141, XP000885069
    - GROTZ W. ET AL, "Effect of ibandronate on bone loss and renal function after kidney transplantation", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, (2001), vol. 12, no. 7, ISSN 1046-6673, pages 1530 - 1537, XP009132609
    - MENSSEN H.D. ET AL, "Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma", JOURNAL OF CLINICAL ONCOLOGY, (200205), vol. 20, no. 9, doi:10.1200/JCO.2002.02.032, ISSN 0732-183X, pages 2353 - 2359, XP009132610

DOI:   http://dx.doi.org/10.1200/JCO.2002.02.032
    - PECHERSTORFER M. ET AL, "Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, (199405), vol. 78, no. 5, ISSN 0021-972X, pages 1268 - 1270, XP009132611
    - "Scientific Discussion", (2004), pages 1 - 29
    - ROCHE, "Bondronat - Fachinformation", (200703), pages 1 - 6
    - ROCHE, "Bondronat 50 mg - Fachinformation", (200709), pages 1 - 4
by applicantUS4972814
    - Remington: The Science and Practice of Pharmacy, (2000), vol. 681
    - ANSEL ET AL., Pharmaceutical Dosage Forms and Drug Delivery Systems
    - POLYMORPHISM IN PHARMACEUTICAL SOLIDS, DRUGS AND THE PHARMACEUTICAL SCIENCES, vol. 95
otherUS4927814
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.